Keyphrases
T-cell Acute Lymphoblastic Leukemia (T-ALL)
58%
Acute Lymphoblastic Leukemia
55%
Leukemia
48%
BCP-ALL
45%
Pediatric Acute Lymphoblastic Leukemia
32%
Leukemia Patients
31%
IKZF1
29%
Working Diagnosis
28%
Minimal Residual Disease
26%
Paediatric B-cell Precursor Acute Lymphoblastic Leukaemia
26%
Steroid Resistance
26%
IKZF1 Deletion
25%
ETV6-RUNX1
16%
Tumor Cells
16%
Pediatric
16%
Cytarabine
16%
Steroid-induced
15%
Genetic Modification
15%
Tumor Protein p53 (TP53)
15%
Notch1
15%
Notch Pathway
14%
GATA3
14%
Response Pathways
14%
Transcriptional Repressor
14%
Subclone
14%
L-asparaginase
13%
Nucleosome Eviction
13%
Genomic Deletion
13%
Dual Targeting
13%
Fusion Gene
13%
Amino Acid Response
13%
Gene Deletion
13%
Tyrosine Kinase 2 (TYK2)
13%
B-cell Translocation Gene 2
13%
CDK4/6 Kinase
13%
Cardiomyocyte Cell Cycle
13%
Neonatal Rat Cardiomyocytes
13%
Bruton's Tyrosine Kinase
13%
Tyrosine Kinase Inhibition
13%
Prognostic Effect
13%
Very Early Relapse
13%
Mineralocorticoid Receptor
13%
Clonal Dynamics
13%
Lineage Decision
13%
Cytotoxicity
13%
Childhood Acute Lymphoblastic Leukemia
13%
Upfront Treatment
13%
Developmental Hematopoiesis
13%
Retinoic Acid
13%
Hyperdiploid
13%
SNAI2
13%
Neuroblastoma Differentiation
13%
Central Pathway
13%
Amino Acid Starvation
13%
Thymus
13%
AKT Pathway
13%
Human Fetus
13%
Developmental Lineage
13%
Glucocorticoid Resistance
13%
Cancer Cells
13%
Myocyte Enhancer Factor 2C (MEF2C)
13%
Cancer-specific
13%
Metabolic Genes
13%
Aberrations
13%
Mutation Accumulation
13%
ERK Pathway
13%
Cell Cycle Arrest
13%
Romidepsin
13%
First Diagnosis
13%
Renal Cell Carcinoma
13%
Pathway Activity
13%
Chromatin Accessibility
13%
Down Syndrome
13%
Histone Deacetylase Inhibitor (HDACi)
13%
Enhancer Element
13%
BTG1
13%
T-cell Leukemia
13%
Human Cancer
13%
Enhancer Activity
13%
Omics Approaches
13%
ERK MAPK
13%
T Cell Development
13%
Molecular Diagnostics
13%
PAX8
13%
Subclonal
13%
Prognostic Relevance
13%
Improved Outcomes
13%
Lymphoid Lineage
13%
Chemotherapy
13%
Signaling Pathway Activity
13%
NR3C1
13%
Subclonal mutations
13%
Notch Signaling Pathway
13%
Mammalian Target of Rapamycin (mTOR)
13%
IKZF1 Gene Deletion
13%
Ara-C
13%
Treatment Response
11%
Treatment Protocol
10%
Hematopoietic Stem Cells
10%
Clinical High Risk
9%
Biochemistry, Genetics and Molecular Biology
B Cell
68%
IKZF1
60%
Precursor
54%
T Cell
41%
Genomics
32%
Enhancer Region
26%
RUNX1
17%
ETV6
17%
Drive
16%
Cytarabine
16%
Nucleosome
13%
Gene Mutation
13%
Tyrosine Kinase 2
13%
Asparaginase
13%
GATA3
13%
Amino Acid Response
13%
Bruton Tyrosine Kinase
13%
Signal Transduction
13%
Mutation Accumulation
13%
P53
13%
Dynamics
13%
Histone Deacetylase
13%
Hematopoiesis
13%
Mineralocorticoid Receptor
13%
Retinoic Acid
13%
Tretinoin
13%
SNAI2
13%
Down Syndrome
13%
Notch Signaling Pathway
13%
Notch
13%
Mitogen-Activated Protein Kinase
13%
Cytotoxicity
13%
Transcriptional Repressor
13%
Cell Maturation
13%
Gene Translocation
13%
Kinase
13%
Phosphotransferase
13%
Mammalian Target of Rapamycin
13%
Cardiac Muscle Cell
13%
Cell Cycle Arrest
13%
PAX8
13%
Gene Deletion
13%
Glucocorticoid
13%
Romidepsin
13%
Cell Cycle Checkpoint
13%
Hematopoietic Cell
12%
WHSC1
10%
Messenger RNA
10%
CRISPR/Cas9
10%
Neural Crest
9%
TCF3
8%
PBX1
8%
Transcription Factors
8%
Event Free Survival
8%
KRAS
6%
Molecular Inversion Probe
6%
High Risk Population
6%
Gene Frequency
6%
PTPN11
6%
Myeloid
5%
Ferroxidase
5%
Ceruloplasmin
5%
Ibrutinib
5%
MEK Inhibitor
5%
Ruxolitinib
5%
Mutation Rate
5%
Trisomy 21
5%
Somatic Mutation
5%
Fetus Development
5%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
100%
Pediatrics
65%
B Cell
55%
Precursor
41%
Leukemia
26%
Minimal Residual Disease
17%
Glucocorticoid
13%
Gene Mutation
13%
Steroid Resistance
13%
Signal Transduction
13%
Protein Tyrosine Kinase
13%
Mineralocorticoid Receptor
13%
Tretinoin
13%
Cytotoxicity
13%
Tamsulosin
13%
Ceruloplasmin
13%
Ganglioneuroblastoma
13%
Phosphotransferase
13%
Cell Cycle Arrest
13%
Clear Cell Renal Cell Carcinoma
13%
Protein P53
13%
Romidepsin
13%
Histone Deacetylase
13%
Gene Translocation
13%
Repressor Gene
13%
Cardiac Muscle Cell
13%
Enhancer Region
13%
Mammalian Target of Rapamycin
13%
Cell Cycle Checkpoint
13%
Chemotherapy
13%
Disease
10%
Transcription Factors
10%
Biological Marker
9%
Event Free Survival
8%
Neural Crest
7%
Neuroblastoma Cell
7%
Leukemia Relapse
6%
Malignant Neoplasm
6%
Pediatrics Patient
6%
Personalized Medicine
6%
Genome Sequencing
6%
Chemotherapy Agent
6%
Screening
6%
Therapy Resistance
6%
Histone Deacetylase Inhibitor
6%
Oncogene
6%
Leukemia Cell
5%
Programmed Cell Death
5%
Cas9
5%
Clustered Regularly Interspaced Short Palindromic Repeat
5%